MOTS-c is a searched research compound with a chemistry distinct from the growth-hormone and repair peptides. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that MOTS-c is an authorized drug or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide that in humans is encoded by the mitochondrial MT-RNR1 gene. It is endogenous — a molecule the body produces, reported to be upregulated in response to exercise. That the peptide occurs naturally is an identity fact; it does not make an injectable research preparation an authorized drug, any more than a molecule’s presence in the body says whether a lyophilized, reconstituted-for-injection material has been assessed by a regulator. A procurement record should still begin with the compound name, that identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document.

Research status

Reference sources describe a lack of robust human data for MOTS-c. The existence of research interest in a named compound documents investigation; it does not establish that a third-party research material is an authorized drug product, equivalent to any study material, or suitable for human use. This article makes no claim about effects.

Canadian and anti-doping regulatory context

Health Canada’s April 2026 public advisory on unauthorized injectable peptides names MOTS-c among the products it identifies, and states that unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. MOTS-c is not approved to treat any medical condition, and it has been banned by the World Anti-Doping Agency beginning in 2024 — relevant to any research setting connected to sport.

The advisory is also explicit that a “research use only” label “does not make these products legal or exempt from regulatory requirements.” Vitatide’s research-use wording should be read the same way — a use boundary, not a claim of regulatory authorization — and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

Read the Health Canada public advisory

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For MOTS-c as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.